Literature DB >> 16968316

Staging practices of primary non-small-cell lung cancer: a literature review.

K Alzahouri1, Y Martinet, S Briançon, F Guillemin.   

Abstract

Lung cancer is the most frequent cause of cancer deaths worldwide, and non-small-cell lung cancer (NSCLC) accounts for approximately 80% of all cases. Stage at diagnosis is the most important indicator of survival. Various non-invasive and invasive procedures are available for NSCLC staging. However, the precise indications for performing these procedures remain controversial. There is no evidence about the level of variability in practice of imaging and invasive procedures used for NSCLC staging. Their high costs contribute to the controversy about their use. We performed a literature search on the MEDLINE database to identify studies reporting practice of staging for a nonselected group of patients with NSCLC. Only seven studies enrolling between 185 and 2,071 patients reported NSCLC staging practices. These studies were reviewed to identify patterns in practice of staging work-up and consecutive treatment. Lack of detailed reporting limits the interpretation of the results. Based on our review, future investigations should be conducted to determine the extent of variation in patterns of physician practices of NSCLC staging and their impact on the treatment practice or patient survival.

Entities:  

Mesh:

Year:  2006        PMID: 16968316     DOI: 10.1111/j.1365-2354.2006.00665.x

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  2 in total

1.  Multi-modality mediastinal staging for lung cancer among medicare beneficiaries.

Authors:  Farhood Farjah; David R Flum; Scott D Ramsey; Patrick J Heagerty; Rebecca Gaston Symons; Douglas E Wood
Journal:  J Thorac Oncol       Date:  2009-03       Impact factor: 15.609

2.  ENTPD5 induces apoptosis in lung cancer cells via regulating caspase 3 expression.

Authors:  Yijun Xue; Lina Wu; Yinan Liu; Yuanyuan Ma; Lijian Zhang; Xuemei Ma; Yue Yang; Jinfeng Chen
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.